ALTEOGEN Inc.
Financials
Valuation Metrics
ALTEOGEN Inc.'s Market Cap is ₩14.8T. At end of 2025 it was ₩24.1T. Ranked #42 of 2,410 in KR market (top 2%), #1 of 1,631 on KOSDAQ (top 0.1%), #3 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 1%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 14.80T KRW | KR#42/2,410 Sec#3/231 |
| Revenue | 254.01B KRW | KR#904/2,410 Sec#45/231 |
| Net Income | 197.79B KRW | KR#148/2,410 Sec#7/231 |
| Total Assets | 739.91B KRW | KR#585/2,410 Sec#33/231 |
| Net Assets | 547.25B KRW | KR#481/2,410 Sec#29/231 |
| Employees | 154 | KR#1,304/2,410 Sec#106/231 |
| Value | ||
| P/E | 74.84x | KR#1,470/2,410 Sec#97/231 |
| P/B | 27.05x | KR#2,399/2,410 Sec#228/231 |
| PEG | 0.65x | KR#731/2,410 Sec#48/231 |
| P/S | 58.27x | KR#2,367/2,410 Sec#199/231 |
| EV/EBITDA | 122.93x | KR#1,509/2,410 Sec#101/231 |
| FCF Yield | 0.68% | KR#1,167/2,410 Sec#88/231 |
| Profitability | ||
| ROE | 36.14% | KR#36/2,410 Sec#3/231 |
| ROA | 26.73% | KR#22/2,410 Sec#4/231 |
| Op. Margin | 47.16% | KR#14/2,410 Sec#3/231 |
| Revenue Growth | 60.71% | KR#156/2,410 Sec#23/231 |
| Earnings Growth | 115.68% | KR#363/2,410 Sec#24/231 |
| Financial Health | ||
| Debt Ratio | 35.21% | KR#692/2,410 Sec#86/231 |
| Total Debt | 4.90B KRW | KR#1,789/2,410 Sec#171/231 |
| FCF | 101.12B KRW | KR#193/2,410 Sec#11/231 |
| Cash | 80.37B KRW | KR#544/2,410 Sec#26/231 |
| Current Ratio | 2.76x | KR#609/2,410 Sec#81/231 |
| Net Debt/EBITDA | -0.63x | KR#462/2,410 Sec#27/231 |
| Dividend | ||
| Div. Yield | 0.13% | KR#1,362/2,410 Sec#84/231 |
| Performance | ||
| 1Y Return | -43.47% | KR#1,761/2,410 Sec#148/231 |
| 1M Return | -18.11% | KR#1,811/2,410 Sec#178/231 |
| From 52W High | -51.46% | KR#1,225/2,410 Sec#97/231 |
| 1Y MDD | -52.06% | KR#1,039/2,410 Sec#84/231 |
| Trading | ||
| Volume | 172,191 shares | KR#309/2,410 Sec#28/231 |
| Trading Value | 36.70B KRW | KR#44/2,410 Sec#4/231 |
| Foreign Own. | 14.92% | KR#321/2,410 Sec#19/231 |
| Per Share | ||
| EPS | 2,839 KRW | KR#356/2,410 Sec#23/231 |
| BPS | 7,857 KRW | KR#1,148/2,410 Sec#85/231 |
Company Info
Established in 2008, Alteogen is a biopharmaceutical research, development, and sales company listed on the KOSDAQ market in 2014. The company holds and researches platform technologies including Hybrozyme™ for converting intravenous to subcutaneous injections, NexP™ for sustained-release biopharmaceuticals, and NexMab™ for next-generation antibody-drug conjugates. It aims to generate technology transfer, service, sales, and royalty revenue through licensing agreements with global multinational pharmaceutical companies. Alteogen is headquartered in Yuseong-gu, Daejeon Metropolitan City.